Skip to main content
. 2019 Jan 20;8(2):128–133. doi: 10.1007/s13730-019-00379-3

Fig. 3.

Fig. 3

Suggested mechanisms of the nephroprotective effects of the triple combination therapy with ARB, GLP-1 receptor agonist and SGLT-2 inhibitor. ARB angiotensin II receptor blocker, GLP-1 glucagon-like peptide-1, SGLT-2 sodium glucose transporter-2